A5016879192- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Kawasaki Disease and Coronary Complications
- Autoimmune and Inflammatory Disorders Research
- Inflammasome and immune disorders
- COVID-19 and Mental Health
- SARS-CoV-2 detection and testing
- SARS-CoV-2 and COVID-19 Research
- Inflammation biomarkers and pathways
- Dermatological and COVID-19 studies
- Cardiovascular Disease and Adiposity
Istanbul University
2021-2022
This study aimed to investigate whether patients regularly using colchicine or hydroxychloroquine (HCQ) have an advantage of protection from coronavirus disease 2019 (COVID-19) developing less severe disease. Patients who were taking HCQ for a rheumatic including Familial Mediterranean Fever, Behçet's syndrome, Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Sjogren's as well their healthy household contacts the control group, included in study. The clinical data regarding COVID-19...
Coronavirus disease-2019 (COVID-19) associated pneumonia may progress into acute respiratory distress syndrome (ARDS). Some patients develop features of macrophage activation (MAS). Elevated levels IL-6 were reported to be with severe disease, and anti-IL-6R tocilizumab has been shown effective in some patients. This retrospective multicenter case-control study aimed evaluate the efficacy hospitalized COVID-19 patients, who received standard care or without tocilizumab. Primary outcome was...
Objective Hyperinflammation (HI) that develops in week 2 of COVID‐19 contributes to a worse outcome. Because laboratory findings can be relatively mild, the available criteria for classification hemophagocytic lymphohistiocytosis or macrophage activation syndrome are not helpful. Methods Our study included discovery cohort patients from Turkey with symptomatic who were followed up while hospitalized during initial wave and replication later period, all whom required oxygen support received...
Background: Hyperinflammation with features of cytokine storm developing in 2nd week COVID-19 contributes to the worse outcome. Because relatively milder inflammatory findings compared other storms, available criteria for classification hemophagocytic lymphohistiocytosis or macrophage activation syndrome (MAS) could not be helpful.Methods: Discovery cohort included symptomatic patients, who were followed at hospital during initial wave. Replication consisted hospitalized patients from a...
Background: COVID-19 runs a severe disease associated with acute respiratory distress syndrome in subset of patients, and hyperinflammatory response developing the second week contributes to worse outcome. Inflammatory features are mostly compatible macrophage activation (MAS) observed other viral infections despite resulting milder changes. Early detection treatment MAS may be better However, available criteria for causes have not been helpful. Objectives: To identify distinct using large...
Background: COVID-19 runs a variable course resulting in acute respiratory distress syndrome and death subset of patients. The entry SARS-CoV-2 into the cell stimulates innate immunity including NLRP3 inflammasome lead to development adaptive later. Hyperinflammatory response with release proinflammatory cytokines IL-1β IL-6 results cytokine storm some patients worse outcome. Colchicine acts on inhibits IL-1 mediated inflammatory attacks gout familial Mediterranean fever (FMF) Patients...